|
**Overview**: Thalassemia Profile (Mumbai) Panel**Introduction**: The Thalassemia Profile (Mumbai) Panel is a diagnostic tool designed for thalassemia screening using whole blood samples. In India, particularly in Mumbai and Western regions with high Sindhi/Gujarati populations, beta-thalassemia carrier rate is ~4-6 percent, with major cases requiring lifelong transfusions. High morbidity from under-screening in urban migrant/rural populations, limited specialized hematology labs, delayed diagnosis leading to complications or unnecessary iron therapy. Per hematology practices aligned with ICMR, National Health Mission, and regional thalassemia programs, the test employs spectrophotometry/HPLC/microscopy for 36 parameters (hemoglobin, RBC/WBC/platelet count, MCV/MCH/MCHC, HbA2/HbF/Hb electrophoresis, iron studies, ferritin, etc., plus molecular screening for HBB) over 1â€"2 days with high accuracy, valuable for carrier detection, major diagnosis, and differentiation from iron deficiency. This diagnostic falls under hematological screening and targets individuals with microcytic anemia, family history, or premarital screening, addressing accurate detection to guide counseling or prenatal testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive thalassemia profiling and reducing major disease incidence in high-prevalence areas. Its whole blood-based approach ensures reliable multi-parameter evaluation.**Other Names**: Thal Profile Mum Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/hematology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Regional thalassemia profiles standard in high-burden cities; in India, Mumbai model for control.**Purpose**: The test assesses 36 parameters including hemoglobin to guide thalassemia screening, detect carrier/major status, inform counseling/therapy.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. PCV, 6. MCV, 7. MCH, 8. MCHC, 9. ESR, 10. HbA2, 11. HbF, 12. HbA, 13. Peripheral Smear, 14. Reticulocyte Count, 15. Iron, 16. TIBC, 17. Ferritin, 18. Transferrin Saturation, 19. RDW, 20. MCV/MCH Ratio, 21. RBC Morphology, 22. Hb Electrophoresis, 23. G6PD, 24. Osmotic Fragility, 25. Bilirubin Total, 26. Bilirubin Direct, 27. ALT, 28. AST, 29. ALP, 30. Total Protein, 31. Albumin, 32. Serum Iron, 33. Serum Ferritin, 34. Blood Group, 35. Coombs Test, 36. Molecular Screening (HBB).**Pretest Condition**: No fasting required; patients should have microcytic anemia or family history.**Specimen**: 3 mL EDTA whole blood, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not frozen (fresh sample preferred for hematology/HPLC).**Medical History**: Patients should provide details on anemia, family thalassemia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected thalassemia including major disease, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using spectrophotometry/HPLC/microscopy by trained personnel to ensure sterile technique and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated HbA2 + low MCV/MCH + molecular HBB mutation indicates beta-thalassemia carrier/major, necessitating specialist input.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Family screening, prenatal testing for confirmation.**Test Limitations**: Iron deficiency overlap; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Thalassemia Studies India 2023. |
